Search companies

Live

CERYVYN THERAPEUTICS LIMITED (ASX: CYV)

Health care · News and insights

CYV: $0.010 -9.09% · MC: $12M

Latest CYV announcements

Ceryvyn Outlines LAM Drug Development Focus as Shares Fall 9%

2026-11-17 · Health care

CYV: $0.010 -9.09% · MC: $12M

Ceryvyn Therapeutics’ November investor presentation highlights CYV-101, an investigational fusion protein it intends to test in lymphangioleiomyomatosis, a rare lung disease; the excerpt provides no new clinical or financial guidance. Shares fell around 9% on the day, alongside the presentation.

Updated 2026-11-17 16:14
Share
SourcesInvestor Presentation
Comments

Ceryvyn Advances LAM Drug Program, Cash Falls To $28 Million

2026-10-29 · Health care

CYV: $0.010 +0.00% · MC: $12M

Ceryvyn Therapeutics says preclinical and inhalation studies for its LAM drug candidate remain on track, and it has contracted to use Xe-MRI in a planned early signal-finding study; an advisory board supported the approach, subject to Stage 1 preclinical requirements. Cash and equivalents fell to approximately $28 million from $30 million at the prior quarter-end, while quarterly operating cash outflow increased from the previous quarter. The company has selected a contract research organisation for the next development stage, with study scope and agreements still to be finalised.

Updated 2026-10-29 09:37
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments